Literature DB >> 25477564

Atorvastatin: multiple sclerosis.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2014        PMID: 25477564      PMCID: PMC4252215          DOI: 10.1310/hpj4910-920

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  9 in total

Review 1.  Statins for multiple sclerosis.

Authors:  Jin Wang; Yousheng Xiao; Man Luo; Hongye Luo
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis.

Authors:  Shilpa Bhardwaj; Craig I Coleman; Diana M Sobieraj
Journal:  Am J Health Syst Pharm       Date:  2012-09-01       Impact factor: 2.637

3.  Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Authors:  O Neuhaus; S Strasser-Fuchs; F Fazekas; B C Kieseier; G Niederwieser; H P Hartung; J J Archelos
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

4.  Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Authors:  Roberta Lanzillo; Giuseppe Orefice; Mario Quarantelli; Carlo Rinaldi; Anna Prinster; Gianluca Ventrella; Daniele Spitaleri; Giacomo Lus; Giovanni Vacca; Barbara Carotenuto; Elena Salvatore; Arturo Brunetti; Gioacchino Tedeschi; Vincenzo Brescia Morra
Journal:  Mult Scler       Date:  2010-02-11       Impact factor: 6.312

Review 5.  Statins as potential therapeutic agents in neuroinflammatory disorders.

Authors:  Olaf Stüve; Sawsan Youssef; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Opin Neurol       Date:  2003-06       Impact factor: 5.710

6.  Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients.

Authors:  C E Teunissen; C D Dijkstra; C H Polman; E L J Hoogervorst; K von Bergmann; D Lütjohann
Journal:  Neurosci Lett       Date:  2003-08-28       Impact factor: 3.046

7.  Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.

Authors:  G Birnbaum; B Cree; I Altafullah; M Zinser; A T Reder
Journal:  Neurology       Date:  2008-06-04       Impact factor: 9.910

8.  Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.

Authors:  Christian Philipp Kamm; Marwan El-Koussy; Sebastian Humpert; Oliver Findling; Ferdinand von Bredow; Yuliya Burren; Guido Schwegler; Dagmar Schött; Filippo Donati; Martin Müller; Norbert Goebels; Felix Müller; Johannes Slotboom; Barbara Tettenborn; Ludwig Kappos; Yvonne Naegelin; Heinrich Paul Mattle
Journal:  J Neurol       Date:  2012-05-09       Impact factor: 4.849

9.  Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Authors:  Friedemann Paul; Sonia Waiczies; Jens Wuerfel; Judith Bellmann-Strobl; Jan Dörr; Helmar Waiczies; Mareile Haertle; Klaus D Wernecke; Hans-Dieter Volk; Orhan Aktas; Frauke Zipp
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.